

HR 4565

Responsibility in Drug Advertising Act of 2016

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 12, 2016

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 19, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/4565>

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]

Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 19, 2016

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 12, 2016)

Responsibility in Drug Advertising Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.

Actions Timeline

- **Feb 19, 2016:** Referred to the Subcommittee on Health.
- **Feb 12, 2016:** Introduced in House
- **Feb 12, 2016:** Referred to the House Committee on Energy and Commerce.